Event Participants
Executives
4 Saurabh Bhandari, Abrarali Dalal, Ramesh Kancharla, Vikas Maheshwari
Analysts
10 Anshul Agrawal, Samy Dea, Bansi Desai, Rahul Jeewani, Damayanti Kerai, Sanketa Kohale, Bala Murali Krishna, Sucrit D. Patil, Prithvi Raj, Ankit Shah
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Operating Revenue | ₹470 crore | +33% YoY; balanced contribution from mature, acquired, and newly commissioned hospitals |
| Like-to-Like Revenue Growth | ~24% YoY | Excluding ~₹38 crore revenue contribution from acquisitions (Guwahati, Warangal) |
| Inpatient Discharges | +28% YoY | Broad-based growth across network including acquired units |
| Outpatient Consultations | +25% YoY | Supported by CRM, digital engagement, and lead conversion initiatives |
| Deliveries | +23% YoY | BirthRight present across all 24-25 hospitals with stickiness benefit |
| Occupancy | >41% | Improved YoY; efficient ALOS maintained |
| ARPOB | +6% YoY | Mature (>5 yrs) units ₹70,000 vs new (<5 yrs) units ₹59,000 (~18% gap); driven by pricing and case mix |
| Total Bed Capacity | 2,435 beds | +26% YoY |
| Operational Bed Capacity | 1,862 beds | +22% YoY |
| EBITDA | ₹134.6 crore | +29.9% YoY; operating discipline despite initial losses at new hospitals |
| EBITDA Margin | 28.6% | Healthy despite ramp-up costs at newly commissioned hospitals |
| PAT | ₹62.5 crore | +16% YoY |
| Cash & Investments | ₹613 crore | As of June 30, 2026; funds expansion pipeline via internal accruals |
| Capital Expenditure (Quarter) | ~₹56 crore | For strengthening existing hospitals and upcoming projects |
| Payer Mix | Cash ~48%, Insurance ~42% | Balanced and consistent with prior quarters |
Geographic & Segment Commentary
South India (Hyderabad, Bengaluru, Chennai, Andhra Pradesh): Core hub-and-spoke markets; Hyderabad at ~1,000 beds continues to add capacity. Bengaluru units (HRBR, Electronic City) are ramping—Rajahmundry is at breakeven and Electronic City expected to breakeven in 2-3 months, against group guidance of 12-18 months for new launches. Andhra Pradesh bed capacity will reach 500 beds with Nellore (70 + 30-bed maternal block) and Guntur (50-bed) additions.
North India (Delhi NCR): Gurugram Sector 56 spoke (Q3 FY28) and Sector 44 hub (Q1 FY29) will focus on quaternary pediatric care—liver/kidney transplant, cardiac surgery, oncology—and international medical tourism, where 10-15% of the pediatric international market is currently unserved. UP, Bihar, Rajasthan, and Haryana together account for ~62% of India's births, underpinning the strategic rationale.
Western India (Mumbai, Pune): Entry into Mumbai via a 100-bed brownfield hospital in Malad (Q1 FY28) serving ~80 lakh population within a 10-12 km radius with a serious shortage of high-quality pediatric beds; differentiators include high-acuity NICU/PICU, aggressive transport/retrieval, and ECMO services. Pune (150 beds) expected in FY29.
Northeast (Guwahati): Acquired platform is EBITDA-positive and performing well; management plans to scale it into a larger multi-specialty hub with future spokes, though doctor scarcity in the region is a key constraint.
Central India (Indore, Raipur, Bhubaneswar): Indore hospital on track for Q3 FY27; Raipur and Bhubaneswar under exploration as high-growth markets with improving economic profiles.
Company-Specific & Strategic Commentary
Five-Year Expansion Roadmap: Plan to add 2,500 beds over five years to reach ~5,000 beds with ~₹2,200 crore CapEx funded through internal accruals; 1,200 beds already in execution. ~30% of new beds in South India, ~70% in new markets (Delhi NCR, northern cities, Central India, Mumbai).
Hub-and-Spoke Model: Five identified hub hospitals (Hyderabad, Bengaluru, Chennai, Gurugram, Guwahati) will drive complex/high-ARPOB quaternary care; spoke hospitals drive high-churn, high-OPD, obstetrics, and NICU volumes. Management avoids sub-50-bed facilities to preserve clinical strength.
Digital & Technology Investments: CRM deployed, lead management and patient conversion systems implemented, digital acquisition spend increased; HIS-SAP middleware with BI/data lake to be perfected over the next 3-4 months.
Acquisition & Integration Strategy: Malad (100-bed, doctor-promoter partners for ~10-year journey), Nellore (70-bed children's hospital + 30-bed maternal block in ~6 months) and Guntur (50-bed ready-to-operate lease) signed; acquired running businesses expected to be EBITDA non-dilutive. Guwahati and Warangal contribute ~10% of group EBITDA.
Clinical Milestones: Pediatric ECMO retrieval team flew 1,800+ km to Guwahati, airlifting a critically ill 8-year-old (36 days on ECMO) in one of India's longest pediatric ECMO retrievals; multidisciplinary rescue of a 13-year-old polytrauma patient with thoracic aorta stent grafting; recognized by the Chief Minister of Assam.
Operating Structure: Cluster-based management planned with hospital heads overseeing 2-4 hospitals; corporate team strengthened with service excellence head and new projects head.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue Growth (Q2 FY27) | "In the range of 20s for sure, not less than that" | Based on operational levers, digital lead conversion; off a higher base |
| Revenue Growth (Medium Term) | ~20% target; top line to double in ~4 years | Aligned with bed expansion trajectory and new-market entry |
| EBITDA Margin (FY27) | 24-25% pre-Ind AS | Reiterated guidance; margin temporarily pressured by ~40% bed additions over last two years |
| Operational Beds (FY27 Exit) | "Well past 2,000" beds | From 1,862 at end-Q1 FY27; includes Indore and other ramp-ups |
| Network Capacity (5 Years) | ~5,000 beds | Requires ~₹2,200 crore CapEx; 1,200 beds in execution, remaining to be identified |
| New Hospital Timelines | Indore Q3 FY27; Malad Q1 FY28; Coimbatore & Gurugram S56 Q3 FY28; Gurugram S44 Q1 FY29; Pune & Bilekahalli FY29 | Committed commencement schedule; Nellore maternal block ~6 months, Guntur ~2 months |
| New Hospital Breakeven | 12-15 months, within 18 months | Rajahmundry at breakeven; Electronic City in 2-3 months |
Risks & Constraints
| Risk | Context |
|---|---|
| EBITDA margin dilution from new bed additions | ~40% of current beds added in last two years; initial losses at new hospitals (HRBR, Electronic City) pressure margins. Management maintains FY27 guidance of 24-25% pre-Ind AS, expecting recovery as units reach breakeven in 12-18 months |
| Mumbai market cost structure | High real-estate and doctor costs against high price points; management could not quantify a profitability target yet, expects ARPOB "at least 20%" higher, and needs time to study the market |
| Seasonality and monsoon deficit | Delayed monsoon may dampen traditional Q2/Q3 seasonal demand; management is deliberately not planning on seasonality and instead driving digital, outreach, and referral levers |
| Doctor availability in Northeast | Paucity of specialists in Guwahati could slow clinical team building for hub expansion; management investing in medical leadership to mitigate |
| Treasury and credit market volatility | With ₹613 crore in cash/investments, credit market turbulence could affect treasury yields; CFO emphasizes liquidity and safety with reasonable industry-standard returns |
| Acquisition integration | Nellore, Guntur, and Malad must be embedded with Rainbow clinical protocols, operating systems, and culture; management expects no EBITDA drag from running acquisitions but ramp-up will take time |
Q&A Highlights
Expansion roadmap and Q2 growth outlook
- Question: Will operational beds reach ~2,050+ by FY27 end; what is the acquisition strategy for Noida/NCR (Samy Dea, Unicorn Asset)
- Answer: Visibility of 1,200 beds already in execution; exploring Noida, Central India, Bhubaneswar, and Raipur where pediatric care demand is under-served. Mumbai entry is a major strategic move with scope to build a larger network. Q2 FY27 revenue growth will "surely be in the range of 20s, not less than that" (Dr. Ramesh Kancharla)
Geographic strategy and new-market economics
- Question: How should Rainbow's five-year footprint evolve; will payer mix change in new geographies (Prithvi Raj, Unifi Capital)
- Answer: Northern states (UP, Bihar, Rajasthan, Haryana) represent ~62% of India's births—opportunity markets; Guwahati to become a larger multi-specialty hub with spokes. Government scheme patients considered only where spare capacity exists, while guarding price points and outcomes. Rajahmundry is at breakeven; Electronic City 2-3 months away (Dr. Ramesh Kancharla; Abrarali Dalal)
Top-line translation and ARPOB trajectory
- Question: How does the 2,500-bed addition translate to revenue growth; what drives ARPOB (Bala Murali Krishna, Oman Investment Advisors)
- Answer: Revenue should more than double from the
2,000-bed base over four years; ARPOB CAGR has been 5-6% over the last five years. Mature units at ₹70,000 vs ₹59,000 for new units (18% gap)—complexity and case mix rise as hospitals mature; Gurugram/Mumbai quaternary care will further push ARPOBs (Dr. Ramesh Kancharla; Vikas Maheshwari)
Mumbai entry: challenges, doctor model, profitability
- Question: Key challenges in Mumbai, doctor engagement model, and expected profitability profile (Damayanti Kerai, HSBC)
- Answer: High-price/high-cost market; Rainbow will bring differentiated clinical value with full-time core pediatric teams (hybridization possible in obstetrics). Profitability target not yet quantified; ARPOB expected at least 20% higher; requires time to study (Dr. Ramesh Kancharla)
Management bandwidth and cluster structure
- Question: Bandwidth to manage aggressive expansion across diverse markets (Rahul Jeewani, IIFL Capital)
- Answer: Corporate team strengthened with service excellence head, new projects head, and sales & marketing head; future cluster structure with hospital heads managing 2-4 hospitals; ~30% of new beds in South, ~70% in new markets (Delhi NCR, northern cities, Central India, Mumbai) (Dr. Ramesh Kancharla; Abrarali Dalal)
Execution priorities and key risks
- Question: Top 2-3 execution priorities and biggest risks; financial cost pressures and receivables (Sucrit D. Patil, Eyesight Fintrade)
- Answer: Priorities are technology/social-media investment (already showing Q1 results) and expanding doctor referral networks. Sees no real competition in the pediatric super-specialty category; complete care continuum (IVF to pediatric super-specialty) drives patient stickiness. Financial focus: integration cost management and treasury yield safety with liquidity (Abrarali Dalal; Vikas Maheshwari)
Replicating success in new markets and seasonality
- Question: Hardest element to replicate in new markets; read on seasonality given monsoon deficit (Bansi Desai, JPMorgan)
- Answer: Hardest is building the clinical ecosystem (doctors/high-potency teams) and communicating capabilities to cities and parents; children's hospitals are emergency-driven, so outcomes determine success. Delhi NCR has recruitment advantages (domestic and international talent). Seasonality not factored into plans—treated as "icing on the cake"; mature-hospital occupancy should continue improving (Dr. Ramesh Kancharla; Abrarali Dalal)
Organic growth split and Bengaluru ramp-up
- Question: Can reported numbers be split into organic/inorganic; quantum of Bengaluru losses (Anshul Agrawal, Emkay)
- Answer: Acquisitions (Guwahati, Warangal) added
₹38 crore revenue (10% of EBITDA); like-to-like revenue growth ~24%. Bengaluru breakeven in 12-15 months, within 18 months; Guwahati is near-company EBITDA, Warangal ramping. Nellore/Guntur are running businesses—no EBITDA drain expected (Vikas Maheshwari; Dr. Ramesh Kancharla)
Mumbai hub potential and Malad growth levers
- Question: Will Mumbai become a hub hospital; growth levers and partner structure at Malad (Ankit Shah, White Equity; Sanketa Kohale, PL Capital)
- Answer: "We certainly would love to have" a large Mumbai hub, but Malad launch is the first priority. Malad catchment is ~80 lakh population within 10-12 km with acute shortage of quality pediatric beds; levers include high-acuity intensive care, aggressive transport/retrieval, and ECMO services. Doctor-promoters will be partners for at least a decade (Dr. Ramesh Kancharla)
Competitive positioning vs Cloudnine and patient stickiness
- Question: How does Rainbow's NCR approach differ from Cloudnine's model (Samy Dea, Unicorn Asset)
- Answer: Cloudnine is largely a digitized delivery/conversion model; Rainbow is a wider tertiary/quaternary pediatric super-specialty platform where deliveries are one part of a full continuum. Stickiness comes from 24/7 pediatric emergency and seamless BirthRight-to-super-specialty transition; management would not build below ~50-80 beds to preserve clinical strength (Abrarali Dalal; Dr. Ramesh Kancharla)
Key Takeaway
Rainbow Children's Medicare delivered a strong Q1 FY27 with operating revenue of ₹470 crore (+33% YoY, 24% like-to-like), EBITDA of ₹134.6 crore (+29.9%, 28.6% margin) and PAT of ₹62.5 crore (+16%), driven by 28%/25%/23% growth in discharges, OPDs and deliveries and 6% ARPOB improvement. Operational beds rose 22% to 1,862 of 2,435 total, with acquisitions (Guwahati, Warangal) contributing ~₹38 crore revenue and ~10% of EBITDA. Management guided to 20%-plus revenue growth in Q2 and the medium term, with FY27 pre-Ind AS EBITDA margins of 24-25% as new units ramp. Strategy centers on adding 2,500 beds over five years (₹2,200 crore CapEx) across five hubs (Hyderabad, Bengaluru, Chennai, Gurugram, Guwahati), entry into Mumbai via Malad, and AP consolidation (Nellore, Guntur; 500 beds), supported by digital CRM and referral-driven demand. Delivering the 5,000-bed network by FY32 now hinges on disciplined execution of the expansion pipeline, profitability of Mumbai/NCR launches, and new-hospital breakeven within 12-18 months.